Results 21 to 30 of about 68,100 (329)
Pharmaceutics, 2023 The development of effective disease-modifying therapies to halt Parkinson’s disease (PD) progression is required. In a subtype of PD patients, alpha-synuclein pathology may start in the enteric nervous system (ENS) or autonomic peripheral nervous system.
Maria Izco +5 more
doaj +1 more source
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Frontiers in Molecular Neuroscience, 2019 Parkinson’s disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease.
Carroll Rutherford Fields +2 more
doaj +1 more source
Alpha-synuclein levels in blood plasma decline with healthy aging. [PDF]
PLoS ONE, 2015 There is unequivocal evidence that alpha-synuclein plays a pivotal pathophysiological role in neurodegenerative diseases, and in particular in synucleinopathies.
Niklas K U Koehler +14 more
doaj +1 more source
Direct detection of alpha synuclein oligomers in vivo [PDF]
, 2014 Background: Rat models of Parkinson’s disease are widely used to elucidate the mechanisms underlying disease etiology or to investigate therapeutic approaches.
Dimant, Hemi +9 more
core +1 more source
Alpha-synuclein modulates dopamine neurotransmission [PDF]
Journal of Chemical Neuroanatomy, 2017 Alpha-synuclein is a small, highly charged protein encoded by the synuclein or SNCA gene that is predominantly expressed in central nervous system neurons. Although its physiological function remains enigmatic, alpha-synuclein is implicated in movement disorders such as Parkinson's disease, multiple system atrophy, and in neurodegenerative diseases ...
Brittany Butler +2 more
openaire +2 more sources
Lipid peroxidation is essential for α-synuclein-induced cell death. [PDF]
, 2015 Parkinson's disease is the second most common neurodegenerative disease and its pathogenesis is closely associated with oxidative stress. Deposition of aggregated α-synuclein (α-Syn) occurs in familial and sporadic forms of Parkinson's disease.
Abramov, AY +5 more
core +2 more sources
Molecular Neurodegeneration, 2010 Background Parkinson's disease (PD) involves the selective damage of dopaminergic neuron cells resulting from the accumulation and fibril formation of alpha-synuclein.
Kobayashi Natsuki +4 more
doaj +1 more source
Gastrointestinal Immunity and Alpha-Synuclein [PDF]
Journal of Parkinson’s Disease, 2019 The gastrointestinal (GI) tract is equipped with robust immune defenses which protect the organism from infection. Enteric nerves are front and center in this defensive network, even in the most primitive organisms. Neuropeptides exhibit potent antimicrobial activity in the vicinity of the nerve and attract the innate and adaptive immune systems to ...
Barbut, Denise +2 more
openaire +2 more sources
Alpha-Synuclein FRET Biosensors Reveal Early Alpha-Synuclein Aggregation in the Endoplasmic Reticulum [PDF]
Life, 2020 Endoplasmic reticulum (ER) dysfunction is important for alpha-synuclein (αS) acquired toxicity. When targeted to the ER in SH-SY5Y cells, transient or stable expression of αS resulted in the formation of compact αS-positive structures in a small subpopulation of cells, resembling αS inclusions. Thus, because of the limitations of immunofluorescence, we
Fabiana Miraglia +8 more
openaire +3 more sources
Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein. [PDF]
, 2014 Accumulation and aggregation of alpha-synuclein in cortical and hippocampal areas is a pathological sign for dementia with Lewy bodies (DLB) and Parkinson's disease with dementia.
Anichtchik, Oleg +4 more
core +2 more sources